Passage Bio reports FY2022 net loss of $136.1M; cash runway into H1 2025; clinical updates for GM1 and FTD

Passage BIO, Inc.

Cash and marketable securities $189.6M at Dec 31, 2022, down from $315.8M; runway into first half of 2025.
FY2022 net loss $136.1M ($2.50 per share) vs $185.4M ($3.48) in 2021; R&D expenses $86.1M.
PBGM01 for GM1 gangliosidosis: interim data shows biological effect; plan to dose first patient at higher dose in H2 2023.
upliFT-D trial for FTD-GRN: enrollment ongoing; initial safety/biomarker data from Cohort 1 expected H2 2023.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Passage BIO, Inc. reported the fourth quarter ended December 31, 2022 results: net income Net loss was $27.1 million, EPS $0.50 per basic and diluted share.

Period: the fourth quarter ended December 31, 2022
Net income: Net loss was $27.1 million
EPS: $0.50 per basic and diluted share
Result: reported results

Exact text from the filing

Net loss was $27.1 million, or a net loss of $0.50 per basic and diluted share, for the quarter

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Passage BIO, Inc. reported the year ended December 31, 2022 results: net income Net loss was $136.1 million, EPS $2.50 per basic and diluted share.

Period: the year ended December 31, 2022
Net income: Net loss was $136.1 million
EPS: $2.50 per basic and diluted share
Result: reported results

Exact text from the filing

$136.1 million, or a net loss of $2.50 per basic and diluted share, for the year ended December 31, 2022

View on SEC.gov

Browse all earnings releases →

Passage BIO, Inc. filing history →

Source: SEC EDGAR

accession 0001558370-23-002831

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.